ArticleFrontiers in medicine2026
Radiomics analysis of dual-energy CT-derived iodine maps for predicting histopathologic grading of pancreatic ductal adenocarcinoma: a two-center study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to develop and validate a nomogram with radiomics features extracted from dual-energy computed tomography (DECT)-derived iodine maps for preoperatively predicting the histopathologic grading in pancreatic ductal adenocarcinoma (PDAC). Materials and methods: In this two-center retrospective analysis, 151 patients were enrolled (82 in the training set; 36 in the testing set, and 33 in the external validation set), all of whom underwent DECT imaging. The radiomics signature was developed using features extracted from DECT-derived portal venous phase (PVP) iodine maps. A clinical model was subsequently established based on significant clinical factors identified through multivariate analysis. The radiomics signature combined with clinically significant features was used to construct the final predictive model. Model performance was assessed through the area under the receiver operating characteristic curve (AUC) and decision curve analysis (DCA). The most predictive model was employed to construct the nomogram, with its calibration accuracy being assessed through calibration plot analysis. Results: The radiomics-clinical model, combining the radiomics signature, body mass index, and carbohydrate antigen 125 levels, showed strong predictive performance for predicting histopathologic grade in PDAC across the training, testing, and external validation datasets, with respective AUCs of 0.873, 0.836, and 0.862. The DCA and calibration curve demonstrated an enhanced overall benefit and demonstrated reliable consistency. Conclusion: The radiomics-clinical model exhibited strong performance in preoperatively predicting the histopathologic grading in patients with PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.